Included CPGs were non-concordant for the recommendation in the 2017 ACC/AHA guideline [22] to prescribe thiazide diuretics or calcium channel blockers as equally preferred option as angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) for first-line therapy in adults with hypertension and chronic kidney disease but without moderately increased albuminuria (ACC-46). The gene discussed is ACE; the disease is chronic kidney disease.